XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 Latest Research
 Infectious Diseases
 Respiratory Medicine
 Public Health
 Clinical Trials
 Medical News
 Awards & Prizes
 Special Topics
 Odd Medical News
 World News

Last Updated: Nov 17th, 2006 - 22:35:04

Nephrology Channel
subscribe to Nephrology newsletter

Latest Research : Nephrology

   DISCUSS   |   EMAIL   |   PRINT
Second-Generation Lanthanum-Based Phosphate Binders Have Potential Role in Treatment of Hyperphosphatemia in End-Stage Renal Disease
Feb 1, 2005, 09:15, Reviewed by: Dr.

Spectrum Pharmaceuticals,Inc.,announced today that it has acquired worldwide exclusive rights to RenaZorb(TM)(two second-generation lanthanum-based phosphate binding agents) from Altair Nanotechnologies, Inc.

These novel non-aluminum, non-calcium phosphate binders which utilize Altair's proprietary lanthanum nanomaterial technology have the potential to treat hyperphosphatemia, i.e., high phosphorus levels in blood, in patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD), with potentially as little as one tablet per meal while currently approved therapies require as many as several tablets per meal.

There are an estimated 340,000 ESRD patients in the U.S. who are on kidney dialysis, and the market for phosphate binding agents was in excess of $600 million in 2004.

According to the National Kidney Foundation, the number of ESRD patients in the U.S. is expected to double over the next decade. In addition, there are an estimated 8.4 million CKD patients, representing a potential multi-billion dollar market opportunity, who are candidates for phosphate binder therapy under the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines, issued in 2003.

Under the terms of the agreement, Spectrum acquired an exclusive worldwide license to develop and commercialize these lanthanum-based phosphate binding agents for all human therapeutic and diagnostic uses. Spectrum will pay to Altair an upfront payment of 100,000 shares of restricted Spectrum common stock and will make an equity investment of $200,000 for 38,314 shares of Altair common stock. In addition, Altair is eligible to receive payments upon achievement of a clinical development and certain regulatory and sales milestones, in addition to royalties on potential net sales.

"This in-licensing of these lanthanum-based phosphate binding agents is an important step in our continued effort to build an extensive and well-diversified portfolio of drug product candidates that span all stages of development and address significant unmet medical needs," stated Rajesh Shrotriya, M.D., Chairman of the Board, Chief Executive Officer and President of Spectrum Pharmaceuticals, Inc. "We are extremely pleased to establish this alliance with Altair. We look forward to advancing these lanthanum-based phosphate binding agents into clinical trials, and pursuing the appropriate regulatory strategy to maximize its potential."

"We are delighted to have the opportunity to work with the Altair team and look forward to developing and commercializing these lanthanum-based phosphate binding agents," stated Luigi Lenaz, M.D., of Spectrum Pharmaceuticals, Inc. "We believe there is a significant unmet medical need for the treatment of hyperphosphatemia, a condition that leads to significant bone disorders and cardiovascular disease, and is associated with a significantly higher death risk in patients with chronic and end-stage kidney disease.

According to K/DOQI Guidelines, fewer than 30 percent of dialysis patients are able to achieve and maintain serum phosphorus levels in the optimal range, despite dietary phosphorus restriction and treatment with currently marketed phosphate binders.

As a non-aluminum, non-calcium phosphate binder, these lanthanum-based phosphate binding agents has the potential to become one of the preferred first-line treatment options for hyperphosphatemia under the new K/DOQI Guidelines because it has the potential to significantly improve patient compliance by lowering the daily pill burden to the lowest-in-class dosage, namely one tablet per meal, and smaller-sized tablets, in addition to a potentially more favorable safety and efficacy profile."

"We are delighted to have a collaborator for the first of our Life Sciences initiatives, these lanthanum-based phosphate binding agents, with the drug development, regulatory and commercialization expertise of Spectrum's management," stated Alan J. Gotcher, Ph. D., Chief Executive Officer of Altair Nanotechnologies, Inc. "We look forward to working with Spectrum to enhance and expedite the development of this promising compound."

"These lanthanum-based phosphate binding agents represents a new generation of high performance phosphate binding drugs that have significant promise in terms of dose and compliance," stated Dr. Ravi Thadhani, M.D., M.P.H. Department of Medicine and Renal Unit, Massachusetts General Hospital, Boston, MA. "The partnership between Altair and Spectrum is an excellent complementary marriage of leaders in their respective fields."

- Spectrum Pharmaceuticals, Inc

Spectrum Pharmaceuticals, Inc

Subscribe to Nephrology Newsletter
E-mail Address:


Spectrum Pharmaceuticals is a specialty pharmaceutical company engaged in the business of acquiring, developing and commercializing proprietary and generic drug products for various indications. The Company's current proprietary drug products are primarily focused on the treatment of cancer and related disorders. The Company's lead drug, satraplatin, is a phase 3 oral, anti-cancer drug being co-developed with GPC Biotech AG, and has been granted fast-track status by the United States Food and Drug Administration (FDA) for its initial indication, second-line chemotherapy for hormone-refractory prostate cancer. Elsamitrucin, a phase 2 drug, is being studied for its initial indication, refractory non-Hodgkin's lymphoma. EOquin(TM), a phase 2 drug, is being studied in the treatment of superficial bladder cancer. SPI-153 (formerly, D-63153), a phase 2 drug, is a 4th generation LHRH antagonist with the potential to treat hormone-dependent cancers as well as benign proliferative disorders, such as benign prostatic hyperplasia and endometriosis. The Company's Abbreviated New Drug Application for ciprofloxacin, a broad-spectrum antibiotic and the generic version of Bayer Corporation's Cipro(R) tablets, received approval from the FDA in September 2004. In addition, the Company has six Abbreviated New Drug Applications pending at the FDA. For additional information kindly visit company's website.

Related Nephrology News

Kidney stones? Have some orange juice!!!
NOTCH2 gene mutations linked to Alagille syndrome
Fetal hydronephrosis mystery solved
Alport Syndrome: From Pathogenesis to a Potential Therapy
Meckel-Gruber syndrome gene identified- a help to understand polycystic kidney disease
Dialysis patients may be overmedicated
Mycophenolate mofetil may be more effective in inducing lupus nephritis remission
Dialysis patients often have close family members also on dialysis - Study
Prognosis Improving For Diabetics With End Stage Renal Disease
Osmolytes critical to survival of kidney cells

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page


© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us